%0 Journal Article %A Alexis Ogdie %A Mei Liu %A Meghan Glynn %A Kelechi Emeanuru %A Leslie R. Harrold %A Sven Richter %A Benoit Guerette %A Philip J. Mease %T Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results %D 2021 %R 10.3899/jrheum.191209 %J The Journal of Rheumatology %P 693-697 %V 48 %N 5 %X Objective Therapeutic response was evaluated among new apremilast, methotrexate (MTX), or biologic disease-modifying antirheumatic drug (bDMARD) initiators with oligoarticular psoriatic arthritis (PsA).Methods Patients with oligoarticular PsA in the Corrona PsA/Spondyloarthritis Registry initiating treatment with apremilast, MTX, or bDMARD, and completing 6-month follow-up were included.Results In total, 150 patients initiated monotherapy (apremilast: n = 34; MTX: n = 15; bDMARD: n = 101). Apremilast initiators had higher baseline disease activity than MTX initiators. At follow-up, apremilast initiators experienced numerically greater disease activity improvements than MTX initiators and similar improvements to bDMARD initiators.Conclusion Findings suggest apremilast monotherapy is an effective option for patients with oligoarticular PsA. %U https://www.jrheum.org/content/jrheum/48/5/693.full.pdf